Compare Twist Bioscience Corp (TWST) vs Weibo Corp (WB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Twist Bioscience Corp vs Weibo Corp — how do they compare? Twist Bioscience Corp trades at $125.52 (market cap $8.42B), while Weibo Corp trades at $6.67 (market cap $1.64B). The key difference: Twist Bioscience Corp is far larger — about 5.1× Weibo Corp's market cap, and Weibo Corp pays a 9.11% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| TWST | WB | |
|---|---|---|
Market Cap | $8.42B | $1.64B |
Sector | Health | Media |
52-Week High | $153.10 | $12.83 |
52-Week Low | $24.16 | $6.63 |
Enterprise Value | $8.35B | $866.57M |
Dividend Yield | — | 9.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Twist Bioscience (TWST) trades at $128.06, up 2.68% today, but remains below the analyst consensus price target of $106.14. The stock shows mixed technical signals with bearish overall momentum but bullish moving averages. Fundamentally, the company continues to report losses with a net income margin of -31.66% despite 23% revenue growth in Q3 2026. Recent news highlights AI-driven optimism and institutional buying interest.
TWST presents a high-risk growth story with strong analyst support (79% buy ratings) but persistent profitability challenges. The stock's valuation appears stretched with P/S of 18.09 and P/B of 18.89. Key catalysts include AI drug discovery partnerships and path to EBITDA breakeven, while risks include cash burn and competitive pressures in biotech.
Weibo (WB) trades at $6.70, down 0.3% on the day, with mixed technical signals showing bearish moving averages but bullish oscillators. Fundamentally, the stock appears undervalued with a P/E of 5.53 and P/B of 0.41, while maintaining strong profitability with 73.36% gross margins and 17.78% net income margin. Recent Q2 2026 earnings beat expectations with $0.38 EPS versus $0.36 expected, though Q1 and Q4 2025 missed estimates.
The investment case balances deep value metrics against structural challenges. While the stock trades below book value and generates substantial cash flow, competitive pressures from Douyin and WeChat threaten long-term relevance. Analyst sentiment is divided with 41% buy ratings but 45% holds, reflecting uncertainty about growth visibility amid declining user metrics. The 8% dividend yield provides downside protection but may not offset fundamental erosion risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →About Weibo Corp
Weibo is the largest social media platform in China. As of 2020, Weibo had 521 million monthly active users and 225 million daily active users, many of whom are drawn there by the millions of key opinion leaders in entertainment, sports, and business circles. Sina is the major shareholder, holding 44.7% of shares and with 70.8% voting power.
Read more on WB →
